Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Isis Pharmaceuticals, Inc. (NQ: ISIS)
20.64 USD  UNCHANGED
Official Closing Price  /  Updated: 8:10 PM EDT, May 23, 2013  /  Add to My Watchlist      
View: Quote News Research
Stories about Isis Pharmaceuticals, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Morning Commentary & Reports For : (OTCQB : JAMN), (NASDAQ : ISIS)
January 31, 2013
category Analyst Recommendations , Stock Market News , BEVERAGES , and 7 more.
from Latest eTeligis Press Releases with 'Plus' ranking
A Down Day for the Indices
January 30, 2013
The stock market indices suffered a down day today, but it was very choppy, advancing early in the morning, and then snapping back by midday as well, but pre-FOMC announcement. The indices then backed... Read More
from Harry's Hotline by Harry Boxer
FDA Approves Isis' Kynamro
January 30, 2013
The Food and Drug Administration approved Isis Pharmaceuticals' (Nasdaq: ISIS) new drug application for its cholesterol treatment Kynamro. The stock price climbed $1.31 to close at $14.69.... Read More
from MarketMinute.com Stock News
Market Wrap for Wednesday, January 30: Stocks Fall as Economy Contracts in Q4
January 30, 2013
The U.S. stock market lost some ground on Wednesday after the fourth-quarter GDP report showed that the economy shrunk by 0.1 percent in the fourth quarter. This compares to consensus estimates which... Read More
category RIMM , Earnings , Benzinga , and 22 more.
from Latest Articles from Benzinga.com
Csrnewsdaily.com Issues Investment Alert On (NASDAQ: AMZN), (NYSE: UIS), (NASDAQ: ISIS), (NASDAQ: GEVO), (NYSE: GOL)
January 30, 2013
category Analyst Recommendations , FINANCING , Stock Market News , and 2 more.
from Latest eTeligis Press Releases with 'Plus' ranking
UPDATE: Piper Jaffray Raises PT to $11 on ISIS Pharmaceuticals on KYNAMRO Approval
January 30, 2013
Piper Jaffray maintained ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS ) with a Neutral rating and raised the price target from $9.00 to $11.00. Piper Jaffray said, "The FDA approved KYNAMRO for Homozygous... Read More
category Benzinga , Piper Jaffray , ISIS , and 3 more.
from Latest Articles from Benzinga.com
Mid-Day Market Update: BlackBerry 10 Release Sends Shares Lower, Isis Pharma Boosts
January 30, 2013
Mid-way through trading Wednesday, the Dow traded up 0.03 percent to 13,958.18 while the NASDAQ was flat at 3,153.18. The S&P fell, decreasing 0.04 percent to 1,507.25. Top Headline Research in Motion... Read More
category RIMM , Earnings , Benzinga , and 20 more.
from Latest Articles from Benzinga.com
Markets Flat As GDP Slips
January 30, 2013
The markets traded flat during the midday with the Dow slipping 11 points to 13,942 as a sharp drop in defense spending weighed down the nation's economy last quarter. Nasdaq added 2 points to 3155. Read More
category Market News
from MarketMinute.com Market Updates
Isis Pharmaceuticals Rising Today on Above-Average Volume (ISIS)
January 30, 2013
from Comtex SmarTrend® News Briefs
Isis Pharmaceuticals Crosses Above its 10-day MA (ISIS)
January 30, 2013
from Comtex SmarTrend® News Briefs
StreetInsider.com Pre-Open Movers 01/30: (CPNO) (CHK) (AMZN) Higher; (CODE) (WBSN) (MTOR) Lower (more...)
January 30, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8042515 for the full story. Read More
from StreetInsider.com News Articles
Isis and Sanofi's Drug OK'd to Treat Inherited Cholesterol Disease
January 30, 2013
Isis Pharmaceuticals (NASDAQ:ISIS) and Sanofi (NYSE:SNY) won US approval to sell the drug Kynamro for a rare inherited condition that raises bad cholesterol and can cause heart disease in young people.... Read More
from Minyanville Headlines
UPDATE: Jefferies Reiterates Underperform Rating, Raises PT on ISIS Pharmaceuticals
January 30, 2013
In a report published Wednesday, Jefferies reiterated its Underperform rating on ISIS Pharmaceuticals (NASDAQ: ISIS ), and slightly raised its price target from $6.50 to $7.00. Jefferies noted,... Read More
category Benzinga , ISIS , Price Target , and 3 more.
from Latest Articles from Benzinga.com
For Isis CEO, A Victory After 24 Years Of Battle
January 30, 2013
Last night, the Food and Drug Administration announced the approval of Kynamro, a new drug to lower cholesterol in patients with homozygous familial hypercholesterolemia (HoFH), a rare genetic disease... Read More
category NASDAQ:SRPT , NYSE:GSK , NASDAQ:BIIB , and 2 more.
from Forbes Real Time
Isis (ISIS), Genzyme (SNY) Receive FDA Approval for KYNAMRO NDA
January 30, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8041509 for the full story. Read More
from StreetInsider.com News Articles
Highlights on Block Activity and Options Trading for Isis Pharmaceuticals (ISIS)
January 30, 2013
NEW YORK (AVAFIN) -- A total of 15 block trades were executed today, typically ... Read More
from AVAFIN
Isis Pharmaceuticals to Provide Update on FDA Approval of KYNAMRO, 09:30 AM ET, Wednesday, January 30, 2013
January 29, 2013
Isis Pharmaceuticals (NASDAQ: ISIS ) announced today that it will conduct a conference call and webcast to provide an update on the U.S. Food and Drug Administration (FDA) approval of the marketing of... Read More
category Management , Benzinga , Guidance , and 2 more.
from Latest Articles from Benzinga.com
FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia
January 29, 2013
The FDA said today that it had granted approval to the novel cholesterol-lowering drug mipomersen sodium for use as an adjunct to diet and drug therapy in patients with homozygous hypercholesterolemia.... Read More
category NYSE:SNY , NASDAQ:ISIS , NASDAQ:AEGR
from Forbes Real Time
FDA Approves Isis Pharmaceuticals (ISIS) drug KYNAMRO
January 29, 2013
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=8040957 for the full story. Read More
from StreetInsider.com News Articles
Uptrend Call Working As Isis Pharmaceuticals Stock Rises 43.1% (ISIS)
January 25, 2013
from Comtex SmarTrend® News Briefs
Lightning Round: EOG Resources, Morgan Stanley & More
January 23, 2013
Are you ready skeedaddy? It's time for the Lightning Round. Cramer makes the call on viewer favorites. Read More
category Westar Energy Inc , Morgan Stanley , Lightning Round , and 9 more.
from CNBC.com News
Isis Pharmaceuticals Shares Up 48.3% Since SmarTrend's Buy Recommendation (ISIS)
January 18, 2013
from Comtex SmarTrend® News Briefs
UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Isis Pharmaceuticals
January 14, 2013
In a report published Monday, BMO Capital Markets reiterated its Outperform rating on Isis Pharmaceuticals (NASDAQ: ISIS ) and raised its price target from $12.00 to $17.00. BMO Capital Markets noted,... Read More
category US4643301090 , Benzinga , BMO Capital Markets , and 4 more.
from Latest Articles from Benzinga.com
Which Six Companies Are in Michael King’s Oncology Wheelhouse?
January 14, 2013
category Pharmaceuticals
from Trefis
35.3% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
January 11, 2013
from Comtex SmarTrend® News Briefs
Holiday Sales Rise 2.5%, Markets Mixed
January 10, 2013
The markets turned mixed during the midday with the Dow rising 23 points to 13,413 as holiday sales rose 2.5% to meet lowered expectations. Nasdaq eased a point to 3104. Read More
category Market News
from MarketMinute.com Market Updates
Mid-Afternoon Market Update: Markets Fall Further, Isis Pharma Rallies
January 08, 2013
Toward the end of trading Tuesday, the Dow traded down 0.43 percent to 13,326.18 while the NASDAQ fell 0.26 percent to 3,090.18. The S&P also fell, decreasing 0.35 percent to 1,456.25. Top Headline... Read More
category US4643301090 , Earnings , CY , and 27 more.
from Latest Articles from Benzinga.com
Isis Pharmaceuticals Up 9.8% Since SmarTrend Uptrend Call (ISIS)
January 03, 2013
from Comtex SmarTrend® News Briefs
Isis Pharmaceuticals, Inc. (ISIS) Shares Cross Above 200 DMA
January 02, 2013
In trading on Wednesday, shares of Isis Pharmaceuticals, Inc. (ISIS) crossed above their 200 day moving average of $10.75, changing hands as high as $10.83 per share. Read More
category Stocks
from Market News Video
Johnson & Johnson, Impax, Isis, Santarus, NuPathe Face Key Dates in January
December 31, 2012
MINYANVILLE ORIGINAL The new year kicks off with a lot of activity for drug and biotech companies including some decisions on new drugs that investors will be following closely. Below are some of the... Read More
from Minyanville Headlines
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here